Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Invested Capital (2020 - 2025)

Barinthus Biotherapeutics' Invested Capital history spans 6 years, with the latest figure at $74.2 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 42.93% year-over-year to $74.2 million; the TTM value through Dec 2025 reached $74.2 million, down 42.93%, while the annual FY2025 figure was $74.2 million, 42.93% down from the prior year.
  • Invested Capital reached $74.2 million in Q4 2025 per BRNS's latest filing, down from $84.6 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $254.8 million in Q2 2022 to a low of -$52.8 million in Q1 2021.
  • Average Invested Capital over 5 years is $175.8 million, with a median of $191.3 million recorded in 2023.
  • The largest YoY upside for Invested Capital was 954.6% in 2021 against a maximum downside of 104.32% in 2021.
  • A 5-year view of Invested Capital shows it stood at $252.7 million in 2021, then dropped by 3.77% to $243.2 million in 2022, then dropped by 23.11% to $187.0 million in 2023, then plummeted by 30.46% to $130.0 million in 2024, then tumbled by 42.93% to $74.2 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Invested Capital are $74.2 million (Q4 2025), $84.6 million (Q3 2025), and $102.5 million (Q2 2025).